Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trials

Table 7 Subgroup analysis of different follow-up periods

Follow-up period	Outcome	No. of studies	Pooled sample size	Heterogeneity			Overall effect
Follow-up period		No. of studies	Pooled sample size	T²	I²	P-value	SMD [95% CI]	P-value
12-24 weeks	BMI	4	307	0.00	0%	0.69	0.47 [0.24, 0.69]	<0.0001
	FPG	7	698	0.03	39%	0.13	-0.08 [-0.27, 0.12]	0.46
	HbA1c	7	698	0.07	61%	0.02	-0.04 [-0.29, 0.20]	0.72
	PPBS	2	297	0.00	0%	0.78	-0.15 [-0.38, 0.08]	0.20
	TC	4	307	0.00	0%	0.98	0.50 [0.27, 0.72]	<0.0001
	HDL	4	307	0.00	0%	0.66	0.12 [-0.10, 0.35]	0.28
	LDL	2	198	0.00	0%	0.36	0.28 [-0.00, 0.56]	0.05
	TG	4	307	0.00	0%	0.65	0.21 [-0.01, 0.44]	0.07
	FINS	5	542	0.05	54%	0.07	0.05 [-0.21, 0.32]	0.69
48-60 weeks	BMI	5	613	0.84	96%	<0.00001	-0.63 [-1.46, 0.20]	0.14
	SBP	4	545	0.26	89%	<0.00001	0.43 [-0.10, 0.96]	0.11
	DBP	4	545	0.27	89%	<0.00001	0.39 [-0.15, 0.93]	0.16
	FPG	7	913	0.04	53%	0.05	0.03 [-0.17, 0.23]	0.77
	HbA1c	6	845	0.00	0%	0.43	0.03 [-0.10, 0.17]	0.65
	PPBS	3	333	0.00	0%	0.95	-0.02 [-0.23, 0.20]	0.88
	TC	4	512	0.37	91%	<0.00001	0.23 [-0.39, 0.86]	0.47
	HDL	4	512	0.53	94%	<0.00001	0.10 [-0.64, 0.84]	0.79
	LDL	3	436	0.00	0%	0.80	0.48 [0.29, 0.67]	<0.00001
	TG	4	512	0.14	80%	0.002	0.31 [-0.11, 0.73]	0.15
	FINS	4	409	1.16	96%	<0.00001	0.14 [-0.94, 1.21]	0.80

ISSN: 1758-5996